On August 6, 2014, the Food and Drug Administration (FDA) approved Orbactiv (oritavancin) to treat acute bacterial skin and skin structure infection (ABSSSI), a leading cause for U.S. hospital admissions. Common types of ABSSSI include cellulitis, erysipelas, surgical or traumatic wound infection, and major cutaneous abscess.
Orbactiv is an intravenous (IV) “second-generation” glycopeptide antibiotic. It has a prolonged half-life, compared with standard vancomycin. This allows Orbactiv to be given in a 1-dose regimen. Orbactiv is the only antibiotic FDA approved to treat ABSSSIs with a single IV administration. Orbactiv is indicated to treat adults with ABSSSI caused by specified susceptible gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).
Three new antibiotics are now FDA approved to treat ABSSSI. In May 2014, the FDA approved Dalvance (dalbavancin; Durata Therapeutics Inc.), an IV antibiotic in the same drug class as Orbactiv. Dalvance is given in 2 doses, spaced 1 week apart. In June 2014, the FDA approved oral and IV Sivextro (tedizolid phosphate; Cubist Pharmaceuticals Inc.). Sivextro is a second-generation oxazolidinone. It is administered once daily for 6 days.